How immune aging affects cancer immunotherapy
How does immune aging affect the likelihood that cancer immunotherapy will work?
It can clarify whether immune aging explains differences in treatment benefit and whether measuring it could help guide immunotherapy choices.
Where it stands now
Main bottleneck
Determining which measurable features of immune aging reliably predict immunotherapy response, including when they signal better or worse outcomes. The review-only evidence trajectory does not establish a validated predictor.
Watch next
A patient study linking defined measures of immune aging to immunotherapy response, with the predictive relationship confirmed in an independent patient group.
Progress timeline
How the evidence has changed over time.
2026 · 2 updates
- Should cancer treatment remove impaired T cells or restore them?Partly supportedSource date 2026-03-06
Since the previous research note · Partly supported
Track continuity
Since the previous research note: When aging changes the immune neighborhood around a tumor
Previous expectation: Interrupting harmful senescence-related interactions around a tumor might improve checkpoint treatment, provided benefit and safety could be demonstrated in patients.
What this study adds: The current review gives this installment a specific immune-cell focus, including mouse-model accounts of BFAR inhibition restoring aged CD8 T-cell function and enhancing anti-PD-1 effects. Its account of tumor-killing senescence-like T cells also sharpens the distinction between removing cells and restoring their functions.
Current research note
- How aging immune cells and tumor surroundings shape treatment in older adultsSource date 2026-03-11
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Should cancer treatment remove impaired T cells or restore them?
Previous expectation: A future adjunct to checkpoint treatment might restore useful T-cell activity and improve cancer control with acceptable toxicity.
What this study adds: The March 11 review connects immune aging with clinical variation across cancers, treatment tolerance and the conditions surrounding tumors. Its experimental examples include both senescent-cell clearance and induced tumor senescence as routes toward improved checkpoint response.
Current research note
2021 · 1 update
- When aging changes the immune neighborhood around a tumorSource date 2021-06-22
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.